Pfizer said on Oct. 7 that it had submitted a request to U.S. drug regulators to expand the authorization for its COVID-19 vaccine to children between the ages of 5 and 11.
The U.S.-based pharmaceutical company and its German partner BioNTech sent the request to the Food and Drug Administration (FDA) about a week after submitting data they said show that the vaccine triggered antibody responses in children in a Phase 2/3 clinical trial. The full results for the trial, which was run by the companies, haven’t yet been released.
